| Subject: | FDA Adverse Event Notice for Oral Sodium Phosphates |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 11 May 2006 - 10:00 am |
| The FDA has issued a notice to healthcare professionals and consumers about reports of acute phosphate nephropathy, a rare, but serious adverse event associated with the use of oral sodium phosphates (OSP) for bowel cleansing.
Documented cases of acute phosphate nephropathy include 21 patients who used an OSP solution (such as Fleet Phospho-soda or Fleet ACCU-PREP) and one patient who used OSP tablets (Visicol).
Individuals at increased risk of acute phosphate nephropathy include the... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
